Synlogic IncChange company Symbol lookupSelect an option...SYBX Synlogic IncMASI Masimo CorpFAZE FaZe Holdings IncSSP E W Scripps CoNHWK NightHawk Biosciences IncELIQ Electriq Power Holdings IncGREE Greenidge Generation Holdings IncOAKU Oak Woods Acquisition CorpWM Waste Management IncWST West Pharmaceutical Services IncGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The Company uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. The Company also has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The Company has also developed two drug candidates through a research collaboration with Ginkgo Bioworks, Inc: SYNB1353, designed to consume methionine for the potential treatment of homocystinuria (HCU), and SYNB2081, designed to lower uric acid for the potential treatment of gout.
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.